Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSC-EVs in Early-Onset Alzheimer's Disease
NCT07554872Phase 1Not yet recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of neural stem cell-derived exosomes in Alzheimer's disease (AD) (3 arms), sponsored by Shanghai Mental Health Center. Primary endpoints: Treatment-Related Adverse Events at 4 weeks and Treatment-Related Clinical Laboratory Abnormalities at 4 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
neural stem cell-derived exosomes
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07554872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554872.